The Bone Morphogenetic Protein Market size was valued at USD 341.26 million in 2024 and is expected to reach USD 504.30 million by 2032, growing at a compound annual growth rate (CAGR) of 5.02% from 2025 to 2032.
Get More Information on Bone Morphogenetic Protein Market - Request Sample Report
The bone morphogenetic protein (BMP) market is growing considerably due to a rise in the number of patients suffering from osteoporosis. Globally, the prevalence of osteoporosis is 18.3%, increasing with age and among women. In the U.S, some 12.6% of adults aged 50 years and older have osteoporosis, and 43.1% have low bone mass (the precursor to osteoporosis), conditions that increase the risk of fractures. Such an increasing occurrence has caused the rapid growth of BMPs, important for new bone formation and healing, particularly in intraspinal and orthopedic surgeries.
Recent developments in MIS and the growing number of spine fusion procedures have even more accelerated the BMP market. Studies have shown that BMPs stimulate bone formation, promote faster healing, and have positive effects on the patient. Furthermore, the population is getting older, and degenerative bone diseases are becoming more prevalent in the world, which has driven the demand for powerful bone regeneration treatment as well. Investigations of developing more effective and safer BMP-like molecules through R&D are also increasing. The potential of BMPs has been acknowledged by regulatory bodies, with approved indications increasing, aiding market expansion.
For instance, recent research has focused on developing stable BMP variants that can be delivered more accurately with the aim of either enhancing the therapeutic effects/or lowering the side effects.
Drivers:
Expanding Applications and Advancing Technologies Fueling Market Growth
Bone morphogenetic protein (BMP) market is primarily driven by the need in the clinic, technical innovation, and a supportive regulatory environment. BMPs have also been increasingly used in various surgical disciplines, ranging from trauma through dental bone augmentation to other reconstructive surgeries.
For instance, an article published in February 2023 in Bone Reports reported improved osteoinductive ability of recombinant BMP-6 in craniofacial repair surgeries. And the demand is only rising, due to the aging population and increasing number of fractures (those related to osteoporosis number more than 8.9 million a year, according to the International Osteoporosis Foundation). Add that to the rapid increase in R&D investment.
In 2023, the U.S. academic-industry partnership received more than USD 15 million in NIH funding for new BMP delivery systems. Regulatory guidance is shifting toward BMPs, with the FDA’s 2023 update to its guidance for combination products easing review pathways for BMP-based bone graft substitutes. Moreover, the abundant availability of recombinant human BMPs (rhBMP-2 and rhBMP-7) resulting from protein engineering facilitates their use in large-scale surgeries. Together, these attributes have translated to improved clinical performance and expanded the therapeutic range of BMPs, establishing them as an indispensable element in bone regeneration procedures.
Restraints:
Safety Concerns, Cost, and Usage Limitations Impede Wider Adoption
The primary concern is safety; for instance, a 2022 study in The Spine Journal found more complications post-surgery, such as unwanted bone growth and inflammation, particularly when BMP-2 is applied in cervical spinal fusion for procedures not officially sanctioned. Furthermore, the high cost of treatment limits the adoption of BMP, particularly in low- and middle-income countries. An average cost for BMP-2 per surgical use can be in excess of USD 5,000, a value that may heavily burden healthcare budgets, particularly when cheaper autograft alternatives are considered. In addition, the market is also stifled by stifling market dynamics through close regulation.
In 2023, EMA released new warnings regarding the use of BMP concerning the risk of adverse events, leading to re-evaluations about the use of BMP in some subpopulations of patients. IP issues and production complexity impede supply-side scale-up and limit the clinical availability. Reimbursement issues in many countries, due to inconsistent clinical outcomes, add more to the friction. In addition, with the lack of extended follow-up data on newer generation BMP analogs, surgeon confidence and patient enthusiasm are diminished. These multifarious barriers indicate that, although BMPs demonstrate considerable promise for the clinic, safety, cost, and regulatory limitations need to be overcome to fully exploit the market potential.
By Type
The rhBMP-2 segment held the majority share in 2024, 74.2% of the overall market. This dominance is due to its powerful osteoinductive properties and broadening clinical use in orthopaedic and spinal procedures. rhBMP-2 has been broadly cleared by such regulatory bodies as the FDA for indications such as lumbar spinal fusion and is thus a surgeon’s top pick. Its excellent applicability and effectiveness in promoting bone healing make it widely used. Furthermore, rhBMP-2 has been the subject of many clinical trials, substantiating its role in generating effective bone healing results.
The rhBMP-7 market is smaller, but is expected to increase at a moderate CAGR as new uses of the treatment are identified in non-union bone fracture treatments and reconstructions. Development is motivated by continued investigation into its magnetic applications in tissue regeneration and musculoskeletal repair.
By Application
The spinal fusion segment was the leading segment in 2024, accounting for a share of 52.3% of the market. This is mostly related to the large number of spinal fusion operations globally, especially in an aging population, and degenerative disc disease or spinal instability. Their successful performance has been driven by the capacity of BMPs, especially rhBMP-2, to obviate the use of autografts and minimize operation time.
The trauma segment is anticipated to register the highest CAGR from 2025 to 2032. This rise is owed to an increasing occurrence of fractures caused by accidents, slips, and sports injuries. Increasing use of BMPs for difficult fractures, particularly in trauma orthopedics, in combination with evidence-based clinical guidelines, is stimulating their application in trauma patients. Progress in BMP localized delivery systems is also improving trauma-based surgery outcomes and is rising the demand in this market.
North America held the majority of the market share in 2024, attributed to a greater number of spinal fusion surgeries, good reimbursement coverage, and a well-developed healthcare system. The U.S. bone morphogenetic protein market size was valued at USD 128.41 million in 2024 and is expected to reach USD 175.82 million by 2032, growing at a compound annual growth rate (CAGR) of 4.06% from 2025 to 2032. Key opinion leaders in the field in the U.S. and Europe are taking the lead, while early adoption of advanced BMP-based solutions is supported by substantial funding of clinical studies in the United States. According to CDC statistics, more than 400,000 spinal fusions are performed each year in the United States, and BMPs, including rhBMP-2, are used in many of them. Its leadership is also reinforced by robust FDA backing for BMP usage and growing orthopedic surgical trends within aging demographics. There are pockets in Canada where use is moderately widespread, largely because of public health approaches and surgical improvements.
The European market is also the second-largest market. High prevalence of osteoarthritis and trauma cases needing bone regeneration are the compelling factors for market growth in this region. Germany has a leading role in the area due to its well-organized network of orthopedic surgery and a large number of clinical BMP studies. The nation also has supportive insurance policies and its extensive use in spinal and dental surgery. France and the UK are both actively helping with research and friendly regulatory routes. Europe is more accepting of the less invasive treatment for bone replacement procedures, and also BMP (Bone Marrow Procedure) in dental and craniofacial reconstruction has driven the market as compared to the U.S/Canada. Nations like Italy and Spain are also trending upwards as elderly populations and trauma cases sideline other patients.
By 2025–2032, Asia Pacific is expected to grow the fastest because of an aging population, growing accident-related injuries, and the development of healthcare infrastructure. The region is primarily led by China, which is being aided by the increasing number of spinal procedures and government-supported biotech developments. There has been an obvious growth of orthopedic operations, and more than 4.5 million bone fractures are reported per year in the country. India and Japan are both contributors of note; India has a growing pool of trauma cases and medical tourism, and an aging Japan means plenty of surgical demand. South Korea and Singapore are contributing to funding for biomedical R&D that can facilitate BMP use in personalized medicine and tissue engineering.
Leading bone morphogenetic protein companies operating in the market comprise Medtronic plc, Cellumed Co., Ltd., Cell Guidance Systems LLC, Merck KGaA, Prospec-Tany Technogene Ltd., Qkine Ltd., Bio-Techne, Thermo Fisher Scientific Inc., Proteintech Group, Inc., and STEMCELL Technologies.
In April 2025, CGBio received FDA Investigational Device Exemption (IDE) approval for Novosis Putty, a novel bone graft material combining rhBMP-2 with a ceramic scaffold. This milestone advances the product’s entry into the U.S. market, enhancing treatment options for spinal fusion and bone regeneration surgeries.
In January 2025, Qkine announced a strategic partnership with ReproCELL to advance the development and commercialization of high-quality recombinant proteins, including Bone Morphogenetic Proteins.
| Report Attributes | Details |
| Market Size in 2024 | USD 341.26 million |
| Market Size by 2032 | USD 504.30 million |
| CAGR | CAGR of 5.02% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (rhBMP-2, rhBMP-7) • By Application (Spinal Fusion, Trauma, Reconstruction, and Oral Maxillofacial) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Medtronic plc, Cellumed Co., Ltd., Cell Guidance Systems LLC, Merck KGaA, Prospec-Tany Technogene Ltd., Qkine Ltd., Bio-Techne, Thermo Fisher Scientific Inc., Proteintech Group, Inc., and STEMCELL Technologies. |
Ans: Bone Morphogenetic Protein Market is anticipated to expand by 5.02% from 2025 to 2032.
Ans: Recombinant Human Bone Morphogenetic Protein-2 segment is expected to held the highest market share in 2024.
Ans: The growth rate of Bone Morphogenetic Protein Market is expected to grow USD 504.30 million by 2032.
Ans: Bone Morphogenetic Protein Market size was valued at USD 341.26 million in 2024.
Ans: Increased expenses of procedure
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Target Conditions (2024)
5.2 Usage Trends of Bone Morphogenetic Proteins, by Application (2024)
5.3 Healthcare Spending on Orthobiologics, by Region and Payer Type (2024)
5.4 Prescription and Adoption Trends of BMP-based Products (2024), by Region
5.5 Regulatory Approval Trends and Product Launches (2021–2024)
5.6 Hospital and ASC Utilization Rates of BMPs (2024)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Bone Morphogenetic Protein Market Segmentation By Type
7.1 Chapter Overview
7.2 RhBMP-2
7.2.1 RhBMP-2 Market Trend Analysis (2021-2032)
7.2.2 RhBMP-2 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 RhBMP-7
7.3.1 RhBMP-7 Market Trends Analysis (2021-2032)
7.3.2 RhBMP-7 Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Bone Morphogenetic Protein Market Segmentation By Application
8.1 Chapter Overview
8.2 Spinal Fusion
8.2.1 Spinal Fusion Market Trends Analysis (2021-2032)
8.2.2 Spinal Fusion Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Trauma
8.3.1 Trauma Market Trends Analysis (2021-2032)
8.3.2 Trauma Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Reconstruction
8.4.1 Reconstruction Market Trends Analysis (2021-2032)
8.4.2 Reconstruction Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Oral Maxillofacial
8.5.1 Oral Maxillofacial Market Trends Analysis (2021-2032)
8.5.2 Oral Maxillofacial Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Bone Morphogenetic Protein Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.2.3 North America Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.4 North America Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.5.2 USA Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.6.2 Canada Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.7.2 Mexico Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.3 Europe
9.3.1 Trends Analysis
9.3.2 Europe Bone Morphogenetic Protein Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.3.3 Europe Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.4 Europe Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.3.5 Germany
9.3.5.1 Germany Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.5.2 Germany Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.3.6 France
9.3.6.1 France Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.6.2 France Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.3.7 UK
9.3.7.1 UK Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.7.2 UK Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.3.8 Italy
9.3.8.1 Italy Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.8.2 Italy Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.3.9 Spain
9.3.9.1 Spain Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.9.2 Spain Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.3.10 Poland
9.3.10.1 Poland Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.10.2 Poland Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.3.11 Turkey
9.3.11.1 Turkey Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.11.2 Turkey Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.3.12 Rest of Europe
9.3.12.1 Rest of Europe Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.12.2 Rest of Europe Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Bone Morphogenetic Protein Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.4.3 Asia Pacific Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.4 Asia Pacific Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 China Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 India Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 Japan Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.6.2 South Korea Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.4.7 Singapore
9.4.7.1 Singapore Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.7.2 Singapore Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
8.4.8 Australia
8.4.8.1 Australia Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
8.4.8.2 Australia Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.4.9 Rest of Asia Pacific
9.4.9.1 Rest of Asia Pacific Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.9.2 Rest of Asia Pacific Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.5 Middle East & Africa
9.5.1 Trends Analysis
9.5.2 Middle East & Africa Bone Morphogenetic Protein Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.5.3 Middle East & Africa Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.4 Middle East & Africa Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.5.5 UAE
9.5.5.1 UAE Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.5.2 UAE Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.5.6 Saudi Arabia
9.5.6.1 Saudi Arabia Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.6.2 Saudi Arabia Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.5.7 Qatar
9.5.7.1 Qatar Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.7.2 Qatar Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.5.8 South Africa
9.5.8.1 South Africa Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.8.2 South Africa Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.5.9 Middle East & Africa
9.5.9.1 Middle East & Africa Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.9.2 Middle East & Africa Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Bone Morphogenetic Protein Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.6.3 Latin America Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.4 Latin America Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.5.2 Brazil Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.6.2 Argentina Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
9.6.7 Rest of Latin America
9.6.7.1 Rest of Latin America Bone Morphogenetic Protein Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.7.2 Rest of Latin America Bone Morphogenetic Protein Market Estimates and Forecasts, By Application (2021-2032) (USD Billion)
10. Company Profiles
10.1 Medtronic plc
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 Cellumed Co., Ltd.
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 Cell Guidance Systems LLC
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 Merck KGaA
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 Prospec-Tany Technogene Ltd.
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 Qkine Ltd.
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 Bio-Techne
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 Thermo Fisher Scientific Inc.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 Proteintech Group Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
10.9.4 SWOT Analysis
10.10 STEMCELL Technologies
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Type
rhBMP-2
rhBMP-7
By Application
Spinal Fusion
Trauma
Reconstruction
Oral Maxillofacial
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players